10.9.2020

Press release: Bruker to distribute ArcDia’s mariPOC® products for automated antigen POCT of COVID-19 and other infectious diseases in Central Europe

Turku, September 10th 2020 – ArcDia International Oy Ltd (“ArcDia”), developer and manufacturer of the innovative mariPOC® platform, has entered into a distribution agreement with Hain Lifescience GmbH, a subsidiary of Bruker Corporation (NASDAQ: BRKR) (“Bruker”). Bruker is the manufacturer of high-end analytical instruments with over 7000 employees globally and over 2 Billion USD in revenues. Bruker is famous in the IVD market for its MALDI Biotyper mass spectrometry system, which today represents the industry standard technology in bacterial identification in central labs.

From now on, Bruker acts as the exclusive distributor for mariPOC® in DACH and Benelux countries and as a non-exclusive distributor in other European countries.  Customers in these countries are encouraged to contact the sales team headed by Mr. Juergen Tressel at Bruker (MicrobiologySales.EMEA[at]bruker.com, https://www.linkedin.com/posts/juergentressel_high-throughput-screening-of-covid-19-symptomatic-activity-6691687949001609216-D5yb).

“We are very pleased to be entering into this agreement with Bruker. The agreement confirms the high market demand for ArcDia’s products. The agreement brings ArcDia an opportunity to reach European customers through Bruker’s sales channel and to better serve the European population during the pandemic and the post pandemic era.”

‒ Mr. Vesa Kemppainen, ArcDia’s CEO ‒

The market demand for decentralized diagnostics and surveillance has surged dramatically since the emergence of COVID-19. ArcDia predicts that the market volume of respiratory infection testing will stay high for years to come.

Rapid and decentralized diagnostic solutions, such as ArcDia’s mariPOC®, are urgently needed in the pandemic era to keep societies up and running and to avoid total lockdown. Multianalyte mariPOC® tests cover COVID-19 and other serious pathogens such as influenza viruses. Thus, the tests serve health care industry well also during influenza season.

‒ Dr. Aleksi Soini, SVP of Business Development at ArcDia ‒

About ArcDia International Ltd

ArcDia International Oy Ltd is a private company focused in the development of innovative products for decentralized testing of infectious diseases. The company based in Turku, Finland, was founded in 2008 and employs 30 skilled professionals. ArcDia is the developer and manufacturer of the mariPOC® IVD platform – an automated system designed for rapid multianalyte identification of pathogens, and detection of inflammation markers and antimicrobial resistance. The current mariPOC® applications cover respiratory tract infections, including COVID-19, tonsillitis and gastrointestinal infections. More information about ArcDia, including mariAST® developed for rapid phenotypic antibiotic resistance testing, and mariCloud™ for real-time epidemiological surveillance, is available at www.arcdia.com.

 

 

Further information, ArcDia:        Mr. Vesa Kemppainen, CEO
ArcDia International Oy Ltd
E-mail: firstname.surename@arcdia.com
Cell/mobile: +358 40 522 7906